Schering-Plough net leaps; Merck & Lilly notch gains

Article Abstract:

The pharmaceuticals industry posted greater profits in the first quarter as sales of some key products increased market share, however there was more competition from generics. Schering-Plough Corp. of the United States tripled profit and Merck & Co. also of the United States saw net profit increase by 11 percent on strong sales of cholesterol drug Zocor. Eli Lilly & Co. of the United States posted a 13 percent profit gain.

United States, Eli Lilly and Co., LLY, Industry forecasts, Industry overview

---

Schering-Plough posts leap in net: Merck profit sinks

Article Abstract:

Pharmaceutical companies Merck & Company Inc. and Schering-Plough Corp. have posted very different earnings. Merck's profit fell 34%, while Schering-Plough's profits rose. Competition from generic drugs, plus expenses related to Vioxx litigation, are partly to blame for Merck's poor showing.

---

Pace of Schering's rebound could ease

Article Abstract:

Schering-Plough Corp. of the United States is planning to heavily finance research which may outpace sales gains this year. Strong sales are driven by allergy drug Claritin and hepatitis B medication. Net income for the fourth quarter soared by 62 percent to $204 million.

Management dynamics, Management, Company business management, Company business forecast/projection, Company forecasts, Financial report

Similar abstracts:

• Abstracts: Merck, Schering-Plough results get boost from cholesterol drugs. Amgen's net income rises 20%; new drugs help Lilly post profit
• Abstracts: Deutsche Telekom net falls 43% on charges. Deutsche Telekom's net rises 9.7%
• Abstracts: Suez net surged 39% in first half on rising prices. Scottish Power reports a profit. Suez's 2005 profit jumped 48% on strength at energy division
• Abstracts: Deutsche Borse is exiting Euronext chase. Deutsche Boerse stays in Euronext race but may seek deal with smaller player
• Abstracts: BP's Libya gas-exploration deal boosts new chief. Results at Exxon, Shell may augur growth slowdown. As oil supplies are stretched, rebels, terrorists get new clout

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.